MANISH GUPTA TO LEAD PHARMA BUSINESS AT STRIDES ARCOLAB

MANISH GUPTA TO LEAD PHARMA BUSINESS AT STRIDES ARCOLAB
Bangalore, May 10, 2010: Strides Arcolab today announced the appointment of Manish Gupta as Chief Executive Officer - Pharma. The appointment follows the restructuring announced by the Company in 2009 and the realignment of its business along three verticals - Pharma, Specialty and Branded Generics. With over 17 years of experience in leading and managing business and performance enhancement across the USA, Europe and India, Manish will be responsible for building and growing Strides Arcolab's Pharma business globally. The Pharma business reported a turnover of Rs 445 crores in FY09.

Manish began his career with A F Ferguson & Co and moved to Khandwala Securities before joining Wockhardt in 1998. His last position at the Wockhardt Group was as Managing Director,Pinewood Healthcare, Ireland & as CEO, Radiant Research, USA. In his 12 years at Wockhardt, Manish handled 13 transactions (including 5 divestments) in USA, Europe and India with EV in excess of US$ 800 million.

"Manish comes with deep business expertise and multi-cultural exposure and we are delighted to have him lead our Pharma business. He imbibes a strong financial discipline in his working style and is a significant addition to the Strides leadership team," said Arun Kumar, Vice Chairman & Group CEO.

"I am delighted to be part of Strides Group at these exciting growth times of the business. I look forward to bringing about sharper focus and performance of the Pharma business," said Manish Gupta.

Manish has a Bachelors Degree in Engineering from the Maharaja Sayajirao University and an MBA with a Major in Finance from the S P Jain Institute of Management, Mumbai.

Strides Arcolab Limited: Leadership through Partnering Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries and has a presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company's website at www.stridesarco.com.
For further information, please contact:
Strides
Mr. Kannan. N (Investors)
+91 80 66580751
Melissa Arulappan (Media)
+91 98450 22389
PR Consultancy
Mahesh Nair, Corporate Voice/Weber Shandwick
+91 9880376648
[email protected]
Kasturi Wasmatkar
+91 9916728393
[email protected]

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.